{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T10:24:55Z","timestamp":1786962295131,"version":"build-2736575974"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01612-w","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T09:34:41Z","timestamp":1786959281000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Determinants of survival after failure of frontline venetoclax plus hypomethylating agent therapy in 356 patients with newly diagnosed acute myeloid leukemia"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2521-6497","authenticated-orcid":false,"given":"Mahnoor","family":"Fatima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momna","family":"Warraich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4252-2619","authenticated-orcid":false,"given":"Kristen","family":"McCullough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0824-3715","authenticated-orcid":false,"given":"Aref","family":"Al-Kali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3609-8404","authenticated-orcid":false,"given":"Hassan B.","family":"Alkhateeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2730-8593","authenticated-orcid":false,"given":"Kebede H.","family":"Begna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2458-9887","authenticated-orcid":false,"given":"Abhishek","family":"Mangaonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5134-7336","authenticated-orcid":false,"given":"Antoine N.","family":"Saliba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5841-4105","authenticated-orcid":false,"given":"William","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5359-336X","authenticated-orcid":false,"given":"Mithun V.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6998-662X","authenticated-orcid":false,"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Animesh","family":"Pardanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1548-918X","authenticated-orcid":false,"given":"Talha","family":"Badar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1673-1708","authenticated-orcid":false,"given":"James","family":"Foran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia Arana","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4605-3821","authenticated-orcid":false,"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-6172","authenticated-orcid":false,"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"1612_CR1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2012971.","journal-title":"N Engl J Med"},{"key":"1612_CR2","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ajh.27246","volume":"99","author":"KW Pratz","year":"2024","unstructured":"Pratz KW, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, D\u00f6hner H, et al. Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024;99:615\u201324. https:\/\/doi.org\/10.1002\/ajh.27246.","journal-title":"Am J Hematol"},{"key":"1612_CR3","doi-asserted-by":"publisher","first-page":"894","DOI":"10.3324\/haematol.2020.252569","volume":"106","author":"A Maiti","year":"2021","unstructured":"Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, et al. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. 2021;106:894\u20138. https:\/\/doi.org\/10.3324\/haematol.2020.252569.","journal-title":"Haematologica"},{"key":"1612_CR4","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.3324\/haematol.2024.286589","volume":"110","author":"C Jim\u00e9nez-Vicente","year":"2025","unstructured":"Jim\u00e9nez-Vicente C, Arribas I, Pomares H, Ramil G, Casta\u00f1o-Diez S, P\u00e9rez-Valencia AI, et al. Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia. Haematologica. 2025;110:1402\u20136. https:\/\/doi.org\/10.3324\/haematol.2024.286589.","journal-title":"Haematologica"},{"key":"1612_CR5","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.3324\/haematol.2022.282677","volume":"108","author":"N Gangat","year":"2023","unstructured":"Gangat N, Ilyas R, Johnson IM, McCullough K, Al-Kali A, Alkhateeb HB, et al. Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy. Haematologica. 2023;108:3170\u20134. https:\/\/doi.org\/10.3324\/haematol.2022.282677.","journal-title":"Haematologica"},{"key":"1612_CR6","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2021012872","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel. Blood. 2022;140:1345\u201377. https:\/\/doi.org\/10.1182\/blood.2021012872.","journal-title":"Blood"},{"key":"1612_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27564","author":"N Gangat","year":"2025","unstructured":"Gangat N, Elbeih A, Ghosoun N, McCullough K, Aperna F, Johnson IM, et al. Mayo genetic risk models for newly diagnosed acute myeloid leukemia treated with venetoclax + hypomethylating agent. Am J Hematol. 2025. https:\/\/doi.org\/10.1002\/ajh.27564.","journal-title":"Am J Hematol"},{"key":"1612_CR8","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135:791\u2013803. https:\/\/doi.org\/10.1182\/blood.2019003988.","journal-title":"Blood"},{"key":"1612_CR9","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1073\/pnas.1324297111","volume":"111","author":"MR Corces-Zimmerman","year":"2014","unstructured":"Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC, Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci USA. 2014;111:2548\u201353. https:\/\/doi.org\/10.1073\/pnas.1324297111.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1612_CR10","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1002\/jha2.791","volume":"4","author":"SA Patel","year":"2023","unstructured":"Patel SA, Cerny J, Gerber WK, Ramanathan M, Ediriwickrema A, Tanenbaum B, et al. Prognostic heterogeneity and clonal dynamics within distinct subgroups of myelodysplastic syndrome and acute myeloid leukemia with TP53 disruptions. EJHaem. 2023;4:1059\u201370. https:\/\/doi.org\/10.1002\/jha2.791.","journal-title":"EJHaem"},{"key":"1612_CR11","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1182\/bloodadvances.2020003734","volume":"5","author":"M Stahl","year":"2021","unstructured":"Stahl M, Menghrajani K, Derkach A, Chan A, Xiao W, Glass J, et al. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML. Blood Adv. 2021;5:1552\u201364. https:\/\/doi.org\/10.1182\/bloodadvances.2020003734.","journal-title":"Blood Adv"},{"key":"1612_CR12","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.3324\/haematol.2022.281214","volume":"107","author":"N Gangat","year":"2022","unstructured":"Gangat N, Johnson I, McCullough K, Farrukh F, Al-Kali A, Alkhateeb H, et al. Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-na\u00efve acute myeloid leukemia. Haematologica. 2022;107:2501\u20135. https:\/\/doi.org\/10.3324\/haematol.2022.281214.","journal-title":"Haematologica"},{"key":"1612_CR13","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.3324\/haematol.2024.286991","volume":"110","author":"IM Johnson","year":"2025","unstructured":"Johnson IM, Ilyas R, McCullough K, Al-Kali A, Alkhateeb HB, Begna KH, et al. Molecular predictors of response and survival in patients with relapsed\/refractory acute myeloid leukemia following venetoclax plus hypomethylating agent therapy. Haematologica. 2025;110:1865\u20139. https:\/\/doi.org\/10.3324\/haematol.2024.286991.","journal-title":"Haematologica"},{"key":"1612_CR14","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","volume":"378","author":"M Jongen-Lavrencic","year":"2018","unstructured":"Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, Al Hinai A, Zeilemaker A, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378:1189\u201399. https:\/\/doi.org\/10.1056\/NEJMoa1716863.","journal-title":"N Engl J Med"},{"key":"1612_CR15","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1080\/10428194.2024.2397570","volume":"65","author":"KB Gil","year":"2024","unstructured":"Gil KB, Abbott D, Amaya ML, Schwartz M, Gutman JA, Kent A, et al. Response to intensive induction chemotherapy after failure of frontline azacitidine and venetoclax in acute myeloid leukemia. Leuk Lymphoma. 2024;65:2228\u201330. https:\/\/doi.org\/10.1080\/10428194.2024.2397570.","journal-title":"Leuk Lymphoma"},{"key":"1612_CR16","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.3324\/haematol.2024.284962","volume":"109","author":"N Steinauer","year":"2024","unstructured":"Steinauer N, McCullough K, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar AA, et al. Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent. Haematologica. 2024;109:2706\u201310. https:\/\/doi.org\/10.3324\/haematol.2024.284962.","journal-title":"Haematologica"},{"key":"1612_CR17","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1200\/JCO.23.01911","volume":"42","author":"NJ Short","year":"2024","unstructured":"Short NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, et al. Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML. J Clin Oncol. 2024;42:1499\u2013508. https:\/\/doi.org\/10.1200\/JCO.23.01911.","journal-title":"J Clin Oncol"},{"key":"1612_CR18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2026034043","author":"ES Wang","year":"2026","unstructured":"Wang ES, Erba HP, Zeidan AM, Roboz GJ, Altman JK, Advani AS, et al. Ziftomenib with venetoclax and azacitidine in relapsed\/refractory NPM1-mutated acute myeloid leukemia. Blood. 2026. https:\/\/doi.org\/10.1182\/blood.2026034043.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01612-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01612-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01612-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T09:34:42Z","timestamp":1786959282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01612-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1612"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01612-w","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"assertion":[{"value":"27 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AK Consulting\/Advisory Role for Novartis. Research funding from Novartis, Celgene, Bristol-Myers Squibb, Astex Pharmaceuticals, Aprea Therapeutics, Hemavant Sciences, ALX Oncology. AAM: Research funding from Bristol-Myers Squibb, Incyte, Novartis, Gilead Sciences. ANS: Consulting\/Advisory Role for Novartis. Research funding from Kura Oncology, Chordia Therapeutics, Daiichi Sankyo\/UCB Japan, Gilead Sciences. MRL: Honoraria from BeiGene, Amgen. Speaker\u2019s Bureau for BeiGene, Amgen. Research funding from Amgen, Astellas, Actinium Pharmaceuticals, Syndax. Travel support from BeiGene, Amgen. MS: Honoraria from Omeros. Research funding from Celgene\/Bristol-Myers Squibb, AbbVie, Kura Oncology, Marker Therapeutics, Astellas. MMP: Consulting\/Advisory Role for Kura Oncology. Honoraria from GlaxoSmithKline, AstraZeneca, CTI\/SOBI. Research funding from Stemline Therapeutics, Epigenetix, Solutherapeutics, Kura Oncology, Polaris. TB: Honoraria from Amgen, Takeda, Syndax, Ascentage Pharma. Research funding from Amgen, Takeda. JF: Consulting\/Advisory Role for Amgen, Takeda, Syndax, Ascentage Pharma. Stock ownership in Aurinia Pharmaceuticals. Research funding from Kura Oncology, Sellas Life Sciences, Celgene\/Bristol-Myers Squibb, Chordia Therapeutics, Takeda, Roivant. Travel support from Peerview. CAY: Consulting\/Advisory Role for Blueprint Medicines, Bristol-Myers Squibb\/Pfizer, Cogent Biosciences. Speaker\u2019s Bureau for Curio Science. Research funding from Blueprint Medicines. Travel support from DAVA Oncology. NG: Advisory Board for Disc Medicine and Agios. The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. This retrospective study was approved by the Mayo Clinic Institutional Review Board (IRB #12-003574), which granted a waiver of informed consent.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"138"}}